Orion Genomics, Novartis Collaborate On Epigenetic Biomarker Research | GenomeWeb

NEW YORK (GenomeWeb News) – Orion Genomics, a St. Louis-based epigenetic research tools and molecular diagnostics company, and Novartis Pharma's molecular diagnostics unit have entered into a multi-year collaboration and license agreement, Orion announced today.

The collaboration, aimed at discovering epigenetic markers related to a range of diseases, will involve mapping DNA methylation across the genome using Orion's MethylScope Technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.